Compare ARK Genomic Revolution ETF (ARKG) vs DraftKings Inc (DKNG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ARK Genomic Revolution ETF vs DraftKings Inc — how do they compare? ARK Genomic Revolution ETF trades at $41.25, while DraftKings Inc trades at $26.72 (market cap $13.14B). The key difference: ARK Genomic Revolution ETF is trading nearer its 52-week high, DraftKings Inc nearer its low. Which is the better fit depends on your goals.
| ARKG | DKNG | |
|---|---|---|
Sector | Sector/Thematic | Consumer Cyclical |
52-Week High | $43.57 | $48.23 |
52-Week Low | $23.09 | $20.72 |
Market Cap | — | $13.14B |
Enterprise Value | — | $14.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
DraftKings (DKNG) trades at $26.48, up 0.7% with neutral technical indicators. The company shows strong revenue growth, reaching $6.05B in 2025 with improving profitability, though valuation ratios remain elevated. Recent expansion into Alberta and launch of DKeX prediction platform signal growth initiatives. Analyst sentiment is bullish with 73% buy ratings and a $34.18 consensus target.
DraftKings presents growth potential through market expansion and product innovation, but faces risks from regulatory scrutiny and competitive pressures. The stock trades below analyst targets but carries high multiples, requiring sustained execution to justify valuation. Key catalysts include World Cup engagement and continued margin improvement.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About DraftKings Inc
DraftKings Inc is a digital sports entertainment and gaming company. The company provides users with daily fantasy sports (DFS), sports betting, and iGaming opportunities and is also involved in the design & development of sports betting and casino gaming platform software for online and retail sportsbook and casino gaming products. It operates in two segments: Business-to-consumer(B2C) and Business-to-Business(B2B), of which the vast majority of its revenue comes from the B2C segment. Geographically, it derives most of its revenue from the United States.
Read more on DKNG →
